Enhancement of Antibodies Neutralize Omicron variants in The Presence of Booster Vaccine Doses and Monoclonal Antibodies

Ali Adel Dawood

doi:10.52711/2349-2988.2022.00015

Research Journal of Science and Technology

ISSN

2349-2988 (Online)
0975-4393 (Print)

Submit Article

Enhancement of Antibodies Neutralize Omicron variants in The Presence of Booster Vaccine Doses and Monoclonal Antibodies

Author(s): Ali Adel Dawood

Email(s): aad@uomosul.edu.iq

DOI: 10.52711/2349-2988.2022.00015

Address: Ali Adel Dawood
Al-Jameaa, 1st, Mosul.
*Corresponding Author

Published In: Volume - 14, Issue - 2, Year - 2022

View HTML

View PDF

ABSTRACT:
The Omicron variant is quickly becoming the most common SARS-CoV-2 virus spreading throughout the world. To understand probable loss of protection against Omicron infection, it's critical to identify declines in viral neutralizing activity in serum of convalescent or vaccinated people. Antibodies against Omicron and various variants have been detected by scientists. These antibodies target non-evolving regions of the viral spike protein. A booster dose improves the quality and amount of the humoral immune response, which has been related to better protection against the disease's more severe signs. Vaccines and boosters must be provided promptly around the world to stop the virus from spreading.

Keywords:

Cite this article:
Ali Adel Dawood. Enhancement of Antibodies Neutralize Omicron variants in The Presence of Booster Vaccine Doses and Monoclonal Antibodies. Research Journal of Science and Technology. 2022; 14(2):95-7. doi: 10.52711/2349-2988.2022.00015

Cite(Electronic):
Ali Adel Dawood. Enhancement of Antibodies Neutralize Omicron variants in The Presence of Booster Vaccine Doses and Monoclonal Antibodies. Research Journal of Science and Technology. 2022; 14(2):95-7. doi: 10.52711/2349-2988.2022.00015 Available on: https://rjstonline.com/AbstractView.aspx?PID=2022-14-2-3

REFERENCES:
1.   Dejnirattisai W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. medRxiv. 2021; 2012.2010.21267534, https://doi.org/10.1101/2021.12.10.21267534.
2.   Aggarwal A. et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. 2021; 2012.2014.21267772. https://doi.org/10.1101/2021.12.14.21267772.
3.   Dawood A, Altobje M, and Alnori H. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. doi:10.52711/0974-360X.2021.00828.
4.   Redd A. D. et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. Preprint at Biorxiv. https://doi.org/10.1101/2021.12.06.471446.
5.   Dawood A, Altobje M, and Alrassam Z. Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. Mikrobio Zhu. 2021; 83(2):82-92. doi: 10.15407/microbiolj83.02.082.
6.   Planas D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Med. 201; 27, 917-924. https://doi.org/10.1038/s41591-021-01318-5.
7.   Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Path. 2022; 154 (105400). https://doi.org/10.1016/j.micpath.2022.105400.
8.   Rappazzo G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021; 371, 823-829. https://doi.org/10.1126/science.abf4830.
9.   Jones E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Trans Med. 2021; 13, eabf1906, https://doi.org/10.1126/scitranslmed.abf1906.
10.   Sun S, Gu H, Cao L, Chen Q, Ye Q, and Yang G, et al. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Nat Commun. 2021; 12, 5654.
11.   Telenti A, Arvin A, Corey L, Corti D, Diamond MS, and Garcia-Sastre A, et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature. 2021; 596, 495e504.